What the business is, and whether it's a good one at a fair price.
Manufactures pharmaceutical formulations on contract for other pharma companies (CDMO), sells trade generics and institutional products in India, and exports formulations to regulated and emerging markets. The CDMO vertical is the dominant business at ₹664 crores in FY26 (+20% Y-o-Y), supplying contract development and manufacturing services to a diversified client base. Trade Generics and Institutional sales contributed ₹195 crores (+13%), while Exports grew 40% to ₹46 crores with Philippines GMP received for Plants 4 and 5 (injectables). Plant 6 reached mechanical completion and is targeted for H1 FY27 commercialisation, with a further 10–15% efficiency upside targeted on top of existing manufacturing capacity that will also include ₹100 crores of injectable capacity. Employee costs at 16.8% of revenue are the largest disclosed cost line; capex is at 7.5% of revenue with FY27 planned as maintenance capex only. The injectable facility has GLP-1 vial-filling capability being evaluated for CDMO opportunities, and Q4 FY26 was the 13th consecutive quarter of record revenue.
Measured from the filed financials, judged against its Pharmaceuticals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from WINDLAS BIOTECH LIMITED's filed financials and exchange disclosures
WINDLAS BIOTECH LIMITED is a Pharmaceuticals & Biotechnology company listed on NSE and BSE, trading under the symbol WINDLAS.
Yes. Over the trailing twelve months WINDLAS BIOTECH LIMITED reported a net profit of ₹66 Cr on revenue of ₹904 Cr.
Yes. The dividend yield is 0.52% at the current price. It paid out 18% of its profit as dividend in FY26.
No. Debt stands at 0.05× equity, and it carries net debt of ₹29 Cr. That is lower than 58% of its 171 Pharmaceuticals peers.
On trailing P/E, WINDLAS BIOTECH LIMITED ranks 99 of 169 in Pharmaceuticals — cheaper than 42% of them, against an industry median of 28.9×. This is a position, not a valuation judgement.
On a typical session WINDLAS BIOTECH LIMITED moves 1.15% — that is the median absolute close-to-close move across its last 269 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by WINDLAS BIOTECH LIMITED appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
